Press Release History - 2013

  • 27 Dec 2013
    ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
  • 20 Dec 2013
    ThromboGenics Appoints Dr David Guyer to its Board of Directors
  • 6 Dec 2013
    ThromboGenics’ Founder Prof Desire Collen Retiring as Chairman
  • 3 Dec 2013
    J-Code for ThromboGenics’ JETREA® to Become Effective January 1, 2014
  • 22 Nov 2013
    ThromboGenics’ Founder Prof Desire Collen Receives Scrip Lifetime Achievement Award
  • 20 Nov 2013
    ThromboGenics’ Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada
  • 19 Nov 2013
    ThromboGenics Short-Listed for Three 2013 Scrip Awards
  • 7 Nov 2013
    ThromboGenics Business Update Q3 2013
  • 23 Oct 2013
    National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics’ JETREA®
  • 21 Oct 2013
    ThromboGenics’ JETREA® Nominated for 2013 Prix Galien USA
  • 17 Oct 2013
    Germany’s G-BA confirms that ThromboGenics’ JETREA® demonstrates significant therapeutic benefits for vitreomacular traction (VMT) patients, including when associated with macular hole
  • 1 Oct 2013
    Euretina Presentation “Adoption of JETREA® in My Everyday Practice” Confirms Need for a New Paradigm in Treatment of symptomatic VMA/VMT, including those cases associated with MH
  • 30 Sep 2013
    ThromboGenics Establishes Level 1 ADR Program for US Investors
  • 5 Sep 2013
    ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
  • 2 Sep 2013
    UK’s NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics’ JETREA® for treatment of Vitreomacular Traction and Macular Hole
  • 29 Aug 2013
    ThromboGenics Business Update H1 2013
  • 16 Aug 2013
    Health Canada approves ThromboGenics’ JETREA® for the treatment of symptomatic vitreomacular adhesion
  • 2 Aug 2013
    ThromboGenics’ JETREA® demonstrates major added value for the Treatment of Vitreomacular Traction and Macular Hole
  • 12 Jun 2013
    ThromboGenics’ JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
  • 28 May 2013
    ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
  • 27 May 2013
    ThromboGenics’ JETREA® Launched in Denmark and Sweden
  • 23 May 2013
    ThromboGenics Supports New Ophthalmology Chair at KU Leuven
  • 16 May 2013
    ThromboGenics Business Update
  • 3 May 2013
    ThromboGenics NV increases share capital through warrant exercises
  • 2 May 2013
    ThromboGenics’ JETREA® available in Germany public and private market
  • 24 Apr 2013
    ThromboGenics’ CEO to Participate in BIO 2013 Interactive Panel: Success Stories: ‘How Emerging Belgian Biotechs are Going Public’
  • 11 Apr 2013
    ThromboGenics’ JETREA®, the first and only medicine for treating vitreomacular traction, now launched in the UK
  • 18 Mar 2013
    ThromboGenics Starts Trading as Part of the BEL20 Index Today
  • 15 Mar 2013
    ThromboGenics’ JETREA® granted EU approval for vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns
  • 14 Mar 2013
    ThromboGenics Announces Business Update and 2012 Full-Year Results
  • 28 Feb 2013
    New Paper in Cell highlights the potential role of TB-403 (anti-PlGF) in the treatment of medulloblastoma, a pediatric brain tumor
  • 18 Jan 2013
    ThromboGenics receives positive CHMP opinion for JETREA®
  • 4 Jan 2013
    ThromboGenics Confirms JETREA® US Launch Date of Monday January 14th, 2013